Top

Current Neurology and Neuroscience Reports

Published in:

01-09-2010

Hormonal Influences on Cognition and Risk for Alzheimer’s Disease

Authors: Sarah C. Janicki, Nicole Schupf

Published in: Current Neurology and Neuroscience Reports | Issue 5/2010

Abstract

Research increasingly suggests that changes in estrogen levels during aging may increase the risk of Alzheimer’s disease, the most common type of dementia. This update reviews the newest information about estrogen and cognitive aging, including information regarding the role of bioavailable estrogen in older women and men, use of selective estrogen receptor modulators to improve cognition, and studies of genetic risk factors to elucidate the effects of endogenous estrogen on aging and cognition. Future trials are needed to determine whether alternate timing, dosage, formulation, or method of administration of hormone replacement can reduce the risk of dementia.

Goodman Y, Bruce AJ, Cheng B, Mattson MP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996, 66:1836–1844.CrossRefPubMed

Toran-Allerand CD, Miranda RC, Bentham WD, et al.: Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1992, 89:4668–4672.CrossRefPubMed

Luine VN: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985, 89:484–490.CrossRefPubMed

Behl C, Widmann M, Trapp T, Holsboer F: 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995, 216:473–482.CrossRefPubMed

Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE: Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 1994, 269:13065–13068.PubMed

Andersen K, Launer LJ, Dewey ME, et al.: Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999, 53:1992–1997.PubMed

Fratiglioni L, Viitanen M, von Strauss E, et al.: Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997, 48:132–138.PubMed

Ganguli M, Dodge HH, Chen P, et al.: Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology 2000, 54:1109–1116.PubMed

Rocca WA, Cha RH, Waring SC, Kokmen E: Incidence of dementia and Alzheimer's disease: a reanalysis of data from Rochester, Minnesota, 1975–1984. Am J Epidemiol 1998, 148:51–62.PubMed

10.

Bachman DL, Wolf PA, Linn RT, et al.: Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 1993, 43:515–519.PubMed

11.

Kawas C, Gray S, Brookmeyer R, et al.: Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000, 54:2072–2077.PubMed

12.

Hebert LE, Scherr PA, Beckett LA, et al.: Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995, 273:1354–1359.CrossRefPubMed

13.

Kukull WA, Higdon R, Bowen JD, et al.: Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002, 59:1737–1746.CrossRefPubMed

14.

Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A: Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 1999, 47:685–691.PubMed

15.

Jacobs DM, Tang MX, Stern Y, et al.: Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998, 50:368–373.PubMed

16.

Paganini-Hill A, Henderson VW: Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994, 140:256–261.PubMed

17.

Tang MX, Jacobs D, Stern Y, et al.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348:429–432.CrossRefPubMed

18.

Yaffe K, Lui LY, Grady D, et al.: Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet 2000, 356:708–712.CrossRefPubMed

19.

Zandi PP, Carlson MC, Plassman BL, et al.: Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002, 288:2123–2129.CrossRefPubMed

20.

• Henderson VW: Aging, estrogens and episodic memory in women. Cogn Behav Neurol 2009, 22:205–214. This is a useful review of the relationships between estrogen exposure and memory in women, with a discussion of the critical-window hypothesis in estrogen supplementation. CrossRefPubMed

21.

Resnick SM, Henderson VW: Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 2002, 288:2170–2172.CrossRefPubMed

22.

Joffe H, Hall JE, Gruber S, et al.: Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause 2006, 13:411–422.CrossRefPubMed

23.

Phillips SM, Sherwin BB: Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992, 17:485–495.CrossRefPubMed

24.

Sherwin BB: Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988, 13:345–357.CrossRefPubMed

25.

Almeida OP, Lautenschlager NT, Vasikaran S, et al.: A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging 2006, 27:141–149.CrossRefPubMed

26.

Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C: Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology 2005, 30:309–315.CrossRefPubMed

27.

Wolf OT, Kudielka BM, Hellhammer DH, et al.: Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels. Psychoneuroendocrinology 1999, 24:727–741.CrossRefPubMed

28.

Maki PM, Gast MJ, Vieweg AJ, et al.: Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 2007, 69:1322–1330.CrossRefPubMed

29.

Linzmayer L, Semlitsch HV, Saletu B, et al.: Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung 2001, 51:238–245.PubMed

30.

Pefanco MA, Kenny AM, Kaplan RF, et al.: The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. J Am Geriatr Soc 2007, 55:426–431.CrossRefPubMed

31.

Resnick SM, Maki PM, Rapp SR, et al.: Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006, 91:1802–1810.CrossRefPubMed

32.

Grady D, Yaffe K, Kristof M, et al.: Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/Progestin Replacement Study. Am J Med 2002, 113:543–548.CrossRefPubMed

33.

Shumaker SA, Reboussin BA, Espeland MA, et al.: The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998, 19:604–621.CrossRefPubMed

34.

Shumaker SA, Legault C, Rapp SR, et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651–2662.CrossRefPubMed

35.

Shumaker SA, Legault C, Kuller L, et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2947–2958.CrossRefPubMed

36.

Nilsen J, Brinton RD: Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci U S A 2003, 100:10506–10511.CrossRefPubMed

37.

• Sano M, Jacobs D, Andrews H, et al.: A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. Clin Trials 2008, 5:523–533. This article describes the design of the PREPARE trial. Although the study results are not yet published, it is anticipated they will address whether there are lasting or delayed effects of HRT on cognition after treatment cessation. CrossRefPubMed

38.

•• Miller VM, Black DM, Brinton EA, et al.: Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009, 2:228–239. This article discusses the design and rationale of KEEPS, which will investigate the critical-timing hypothesis of estrogen supplementation by evaluating the effects of HRT on a younger female population. CrossRefPubMed

39.

Early vs Late Intervention Trial with Estradiol (ELITE). Available at http://clinicaltrials.gov/ct2/show/NCT00114517. Accessed March 2010.

40.

Yaffe K, Grady D, Pressman A, Cummings S: Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women . J Am Geriatr Soc 1998, 46:816–821.PubMed

41.

Lebrun CE, van der Schouw YT, de Jong FH, et al.: Endogenous oestrogens are related to cognition in healthy elderly women. Clin Endocrinol (Oxf) 2005, 63:50–55.CrossRef

42.

Schupf N, Pang D, Patel BN, et al.: Onset of dementia is associated with age at menopause in women with Down's syndrome. Ann Neurol 2003, 54:433–438.CrossRefPubMed

43.

Hoskin EK, Tang MX, Manly JJ, Mayeux R: Elevated sex-hormone binding globulin in elderly women with Alzheimer's disease. Neurobiol Aging 2004, 25:141–147.CrossRefPubMed

44.

Schupf N, Winsten S, Patel B, et al.: Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down syndrome. Neurosci Lett 2006, 406:298–302.CrossRefPubMed

45.

Geerlings MI, Launer LJ, de Jong FH, et al.: Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol 2003, 53:607–615.CrossRefPubMed

46.

Yaffe K, Barnes D, Lindquist K, et al.: Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging 2007, 28:171–178.CrossRefPubMed

47.

Carlson LE, Sherwin BB: Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory. Menopause 2000, 7:168–177.CrossRefPubMed

48.

Young LA, Neiss MB, Samuels MH, et al.: Cognition is not modified by large but temporary changes in sex hormones in men. J Clin Endocrinol Metab 2010, 95:280–288.CrossRefPubMed

49.

Kampen DL, Sherwin BB: Estradiol is related to visual memory in healthy young men. Behav Neurosci 1996, 110:613–617.CrossRefPubMed

50.

Hogervorst E, De Jager C, Budge M, Smith AD: Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocrinology 2004, 29:405–421.CrossRefPubMed

51.

Senanarong V, Vannasaeng S, Poungvarin N, et al.: Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. Arch Neurol 2002, 59:385–389.CrossRefPubMed

52.

Wolf OT, Kirschbaum C: Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men . Horm Behav 2002, 41:259–266.CrossRefPubMed

53.

Lessov-Schlaggar CN, Reed T, Swan GE, et al.: Association of sex steroid hormones with brain morphology and cognition in healthy elderly men. Neurology 2005, 65:1591–1596.CrossRefPubMed

54.

Matousek RH, Sherwin BB: A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology 2010, 35:215–225.CrossRefPubMed

55.

Geerlings MI, Strozyk D, Masaki K, et al.: Endogenous sex hormones, cognitive decline, and future dementia in old men. Ann Neurol 2006, 60:346–355.CrossRefPubMed

56.

Cherrier MM, Matsumoto AM, Amory JK, et al.: Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology 2007, 32:72–79.CrossRefPubMed

57.

Beer TM, Bland LB, Bussiere JR, et al.: Testosterone loss and estradiol administration modify memory in men. J Urol 2006, 175:130–135.CrossRefPubMed

58.

Kenny AM, Bellantonio S, Gruman CA, et al.: Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2002, 57:M321–M325.PubMed

59.

Taxel P, Stevens MC, Trahiotis M, et al.: The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. J Am Geriatr Soc 2004, 52:269–273.CrossRefPubMed

60.

Janowsky JS, Chavez B, Orwoll E: Sex steroids modify working memory. J Cogn Neurosci 2000, 12:407–414.CrossRefPubMed

61.

Cherrier MM, Matsumoto AM, Amory JK, et al.: The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005, 64:290–296.CrossRefPubMed

62.

Sherwin BB, Chertkow H, Schipper H, Nasreddine Z: A randomized controlled trial of estrogen treatment in men with mild cognitive impairment. Neurobiol Aging (Epub ahead of print).

63.

Yaffe K, Lui LY, Zmuda J, Cauley J: Sex hormones and cognitive function in older men. J Am Geriatr Soc 2002, 50:707–712.CrossRefPubMed

64.

Yaffe K, Krueger K, Cummings SR, et al.: Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005, 162:683–690.CrossRefPubMed

65.

Legault C, Maki PM, Resnick SM, et al.: Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol 2009, 27:5144–5152.CrossRefPubMed

66.

•• Espeland MA, Shumaker SA, Limacher M, et al.: Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt) 2010, 19:371–379. This secondary analysis study raises the possibility that both tamoxifen and raloxifene adversely affect cognitive function in older women; however, the magnitude of the effect is small and the long-term consequences are unknown.CrossRef

67.

Brandi ML, Becherini L, Gennari L, et al.: Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease. Biochem Biophys Res Commun 1999, 265:335–338.CrossRefPubMed

68.

Corbo RM, Gambina G, Ruggeri M, Scacchi R: Association of estrogen receptor alpha (ESR1) PvuII and XbaI polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations. Dement Geriatr Cogn Disord 2006, 22:67–72.CrossRefPubMed

69.

Isoe-Wada K, Maeda M, Yong J, et al.: Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia. Eur J Neurol 1999, 6:431–435.CrossRefPubMed

70.

Ji Y, Urakami K, Wada-Isoe K, et al.: Estrogen receptor gene polymorphisms in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia. Dement Geriatr Cogn Disord 2000, 11:119–122.CrossRefPubMed

71.

Schupf N, Lee JH, Wei M, et al.: Estrogen receptor-alpha variants increase risk of Alzheimer’s disease in women with Down syndrome. Dement Geriatr Cogn Disord 2008, 25:476–482.CrossRefPubMed

72.

Pirskanen M, Hiltunen M, Mannermaa A, et al.: Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. Eur J Hum Genet 2005, 13:1000–1006.CrossRefPubMed

73.

Forsell C, Enmark E, Axelman K, et al.: Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease. Eur J Hum Genet 2001, 9:802–804.CrossRefPubMed

74.

• Yaffe K, Lindquist K, Sen S, et al.: Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the Health ABC study. Neurobiol Aging 2009, 30:607–614. This study’s findings that several SNPs in the ESR1 and ESR2 genes were associated with risk of developing cognitive impairment suggest that ER genetic variants might play a role in cognitive aging.CrossRefPubMed

75.

Huang R, Poduslo SE: CYP19 haplotypes increase risk for Alzheimer's disease. J Med Genet 2006, 43:e42.CrossRefPubMed

76.

Iivonen S, Corder E, Lehtovirta M, et al.: Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease. Neurology 2004, 62:1170–1176.PubMed

77.

Butler HT, Warden DR, Hogervorst E, et al.: Association of the aromatase gene with Alzheimer's disease in women. Neurosci Lett 2010, 468:202–206.CrossRefPubMed

78.

Corbo RM, Gambina G, Ulizzi L, et al.: Genetic variation of CYP19 (aromatase) gene influences age at onset of Alzheimer’s disease in women. Dement Geriatr Cogn Disord 2009, 27:513–518.CrossRefPubMed

Title: Hormonal Influences on Cognition and Risk for Alzheimer’s Disease
Authors: Sarah C. Janicki
Nicole Schupf
Publication date: 01-09-2010
Publisher: Current Science Inc.
Published in: Current Neurology and Neuroscience Reports / Issue 5/2010
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-010-0122-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hormonal Influences on Cognition and Risk for Alzheimer’s Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

What Can We Learn From Freezing of Gait in Parkinson’s Disease?

Tarenflurbil in Patients with Mild Alzheimer’s Disease

Consent in Impaired Populations

Physical Activity and Mild Cognitive Impairment and Alzheimer’s Disease

Emerging Oral Therapies in Multiple Sclerosis

Postural Control in Multiple Sclerosis: Implications for Fall Prevention